Skip to main content
. 2012 Mar 30;54(12):1699–1709. doi: 10.1093/cid/cis270

Figure 5.

Figure 5.

Cumulative mortality and cumulative noncure rate analyses for the tigecycline noninferiority trials identified in this meta-analysis from mid-2005 (the date when tigecycline received FDA approval as monotherapy for complicated intra-abdominal and skin infections) through the end of 2009 (the date by which the last study in this meta-analysis was completed).